Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

1. (Currently amended) A method of treating ~~a patient in need thereof~~ an individual comprising administration of a composition comprising cord blood or cord blood-derived stem cells, wherein said administration delivers at least [[5×10^9]] 1×10^{10} total nucleated cells, or at least 1×10^9 stem cells, to an individual in need of said administration.

2. (Currently amended) The method of claim [[2]] 1 wherein the cord blood or cord blood-derived stem cells are suitable for bone marrow transplantation.

3. (Original) The method of claim 2 wherein the cord blood or cord blood-derived stem cells are suitable for administration in humans.

4. (Currently amended) The method of claim 2 wherein a plurality of the cord blood-derived stem cells express the cell surface markers $CD34^+$ and $CD38^-$.

~~cord blood stem cells.~~

5. (Original) The method of claim 2 wherein a plurality of the umbilical cord blood stem cells express the cell surface markers CD34+ and CD38+.

6. (Currently amended) The method of claim 2 ~~wherein~~ additionally comprising contacting the cord blood or cord blood-derived stem cells ~~is treated~~ with a growth factor.

7. (Original) The method of claim 6 wherein the growth factor is a cytokine, lymphokine, interferon, colony stimulating factor (CSF), interferon, chemokine, interleukin, human hematopoietic growth factor, hematopoietic growth factor ligand, stem cell factor, thrombopoietin (Tpo), granulocyte colony-stimulating factor (G-CSF), leukemia inhibitory factor, basic fibroblast growth factor, placenta derived growth factor or epidermal growth factor.

8. (Currently amended) The method of claim 6 wherein the cord blood or cord blood-derived stem cells ~~is treated~~ are contacted with the growth factor to induce differentiation into a plurality of cell types.

9. (Currently amended) The method of claim 6 wherein the cord blood or cord blood-derived stem cells ~~is treated~~ are contacted treated with the growth factor to prevent or suppress differentiation into a particular cell type.

10. (Original) A method of treating myelodysplasia which comprises administering cord blood or cord blood-derived stem cells to a patient in need thereof.

11. (Currently amended) The method of claim 1 wherein said administration delivers at least [[5 x 10^9]] 3 x 10^{10} total nucleated cells or at least 3 x 10^9 stem cells.

12. (Canceled)

13. (Currently amended) The method of claim 1 wherein said administration delivers at least [[20 x 10^9]] 2 x 10^{10} total nucleated cells or at least 2 x 10^9 stem cells.

14. (Currently amended) The method of claim 1 wherein said ~~patient~~ individual has a disease, disorder or condition that includes an inflammation component.

15. (Currently amended) The method of claim 1 wherein said ~~patient~~ individual has a vascular disease, disorder or condition.

16. (Original) The method of claim 15 wherein said disease, disorder or condition is atherosclerosis.

17. (Currently amended) The method of claim 1 wherein said individual has ~~disease, disorder or condition is~~ a neurological disease, disorder or condition.

18. (Currently amended) The method of claim 17, wherein said disease, disorder or condition is selected from the group consisting of ~~amyletrophie~~ amyotrophic lateral sclerosis and multiple sclerosis.

19. (Currently amended) The method of claim 1, wherein said ~~patient~~ individual has an autoimmune disorder.

20. (Canceled)

21. (Currently amended) The method of claim 1, wherein said individual has undergone a ~~condition is caused by or associated with~~ trauma or injury.

22. (Original) The method of claim 21, where said trauma or injury is trauma or injury to the central nervous system.

23. (Original) The method of claim 21, wherein said trauma or injury is trauma or injury to the peripheral nervous system.

24. (Currently amended) The method of claim 1, wherein said at least ~~5 x 10^9~~ 1 x 10^{10} total nucleated cells, or at least 1 x 10^9 stem cells, comprises cells derived from a plurality of donors.

25. (Original) The method of claim 1 wherein none of said cells in said composition is HLA-typed prior to said administration.

26. (Original) The method of claim 1 wherein said composition is preconditioned for between 18 hours and 21 days prior to said administration.

27. (Original) The method of claim 1 wherein said composition is preconditioned for between 48 hours and 10 days prior to said administration.

28. (Original) The method of claim 1, wherein said composition is preconditioned for between 3-5 days prior to said administration.